{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:37:53Z","timestamp":1791581873122,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40123-024-00898-y","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:02:11Z","timestamp":1707696131000},"page":"995-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03519386","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2720","authenticated-orcid":false,"given":"Steven R.","family":"Sarkisian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-2923","authenticated-orcid":false,"given":"Robert E.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7405","authenticated-orcid":false,"given":"John P.","family":"Berdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian B.","family":"Heersink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0572-2236","authenticated-orcid":false,"given":"Long V.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry G.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Applegate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7971-5292","authenticated-orcid":false,"given":"Angela C.","family":"Kothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-0652","authenticated-orcid":false,"given":"Dale W.","family":"Usner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jay","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3577-3096","authenticated-orcid":false,"given":"Tomas","family":"Navratil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"1","key":"898_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/ICL.0000000000000301","volume":"44","author":"J Stringham","year":"2018","unstructured":"Stringham J, Ashkenazy N, Galor A, Wellik SR. Barriers to glaucoma medication compliance among veterans: dry eye symptoms and anxiety disorders. Eye Contact Lens. 2018;44(1):50\u20134.","journal-title":"Eye Contact Lens"},{"issue":"5","key":"898_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","volume":"112","author":"AL Robin","year":"2005","unstructured":"Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863\u20138.","journal-title":"Ophthalmology"},{"issue":"5","key":"898_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ophtha.2009.10.038","volume":"117","author":"G Rees","year":"2010","unstructured":"Rees G, Leong O, Crowston JG, Lamoureux EL. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. 2010;117(5):903\u20138.","journal-title":"Ophthalmology"},{"key":"898_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jtos.2023.05.012","volume":"29","author":"M Kolko","year":"2023","unstructured":"Kolko M, Gazzard G, Baudouin C, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocul Surf. 2023;29:456\u201368.","journal-title":"Ocul Surf"},{"key":"898_CR5","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.2147\/OPTH.S439457","volume":"17","author":"S Bedrood","year":"2023","unstructured":"Bedrood S, Berdahl J, Sheybani A, Singh IP. Alternatives to topical glaucoma medication for glaucoma management. Clin Ophthalmol. 2023;17:3899\u2013913.","journal-title":"Clin Ophthalmol"},{"key":"898_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2020;127:477\u201383.","journal-title":"Ophthalmology"},{"issue":"12","key":"898_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/IJG.0000000000001943","volume":"30","author":"YH Shu","year":"2021","unstructured":"Shu YH, Wu J, Luong T, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US health care system. J Glaucoma. 2021;30(12):1047\u201355.","journal-title":"J Glaucoma"},{"issue":"3","key":"898_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/IJG.0000000000001982","volume":"31","author":"AP Ranjala","year":"2022","unstructured":"Ranjala AP, Prager AJ, Park MS, Tanna AP. Association of the effectiveness of eye drop self-instillation and glaucoma progression. J Glaucoma. 2022;31(3):156\u20139.","journal-title":"J Glaucoma"},{"issue":"4","key":"898_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598\u2013606.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"898_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","volume":"130","author":"G Gazzard","year":"2023","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139\u201351.","journal-title":"Ophthalmology"},{"issue":"7","key":"898_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/IJG.0b013e318218287f","volume":"21","author":"LJ Katz","year":"2012","unstructured":"Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012;21(7):460\u20138.","journal-title":"J Glaucoma"},{"key":"898_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.21037\/aes.2019.05.01","volume":"4","author":"Y Guo","year":"2019","unstructured":"Guo Y, Ioannidou A, Jute P. Selective laser trabeculoplasty: a review of repeatability. Ann Eye Sci. 2019;4:20.","journal-title":"Ann Eye Sci"},{"issue":"11","key":"898_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/bjo.2004.052795","volume":"89","author":"M Nagar","year":"2005","unstructured":"Nagar M, Ogunyomade A, O\u2019Brart DP, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89(11):1413\u20137.","journal-title":"Br J Ophthalmol"},{"key":"898_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/OPTH.S84996","volume":"10","author":"J Song","year":"2016","unstructured":"Song J. Complications of selective laser trabeculoplasty: a review. Clin Ophthalmol. 2016;10:137\u201343.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"898_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5005\/jp-journals-10008-1114","volume":"6","author":"CI Clement","year":"2012","unstructured":"Clement CI. Initial treatment: prostaglandin analog or selective laser trabeculoplasty. J Curr Glaucoma Pract. 2012;6(3):99\u2013103.","journal-title":"J Curr Glaucoma Pract"},{"issue":"17","key":"898_CR16","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, et al. Phase\u00a03, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017\u201333.","journal-title":"Drugs"},{"issue":"12","key":"898_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","volume":"127","author":"FA Medeiros","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, et al. Phase\u00a03, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627\u201341.","journal-title":"Ophthalmology"},{"key":"898_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","volume":"84","author":"JP Berdahl","year":"2024","unstructured":"Berdahl JP, Sarkisian SR, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. 2024;84:83\u201397.","journal-title":"Drugs"},{"issue":"11 Suppl","key":"898_CR19","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.ophtha.2009.06.022","volume":"116","author":"DL Budenz","year":"2009","unstructured":"Budenz DL. A clinician\u2019s guide to the assessment and management of nonadherence in glaucoma. Ophthalmology. 2009;116(11 Suppl):S43\u20137.","journal-title":"Ophthalmology"},{"key":"898_CR20","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s40123-023-00797-8","volume":"12","author":"SG Moore","year":"2023","unstructured":"Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: a narrative review. Ophthalmol Ther. 2023;12:2863\u201380.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"898_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1543-5946(03)90003-1","volume":"1","author":"R Balkrishnan","year":"2003","unstructured":"Balkrishnan R, Bond JB, Byerly WG, Camacho FT, Anderson RT. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization. Am J Geriatr Pharmacother. 2003;1(2):75\u201381.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"898_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1\u20139.","journal-title":"Am J Ophthalmol"},{"key":"898_CR23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12325-016-0333-6","volume":"33","author":"L Quaranta","year":"2016","unstructured":"Quaranta L, Riva I, Gerardi C, et al. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33:959\u201381.","journal-title":"Adv Ther"},{"key":"898_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am JOphthalmol. 2001;132:472\u201384.","journal-title":"Am JOphthalmol"},{"issue":"5","key":"898_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00061198-200110000-00010","volume":"10","author":"I Goldberg","year":"2001","unstructured":"Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414\u201321.","journal-title":"J Glaucoma"},{"issue":"3","key":"898_CR26","first-page":"238","volume":"6","author":"C Patradul","year":"2017","unstructured":"Patradul C, Tantisevi V, Manassakorn A. Factors related to prostaglandin-associated periorbitopathy in glaucoma patients. Asia Pac J Ophthalmol (Phila). 2017;6(3):238\u201342.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"898_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ceo.12163","volume":"42","author":"M Kucukevcilioglu","year":"2013","unstructured":"Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exper Ophthalmol. 2013;42(2):126\u201331.","journal-title":"Clin Exper Ophthalmol"},{"issue":"5","key":"898_CR28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688\u2013703.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"898_CR29","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/S0039-6257(97)80020-3","volume":"41","author":"PJ Wistrand","year":"1997","unstructured":"Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(2):S129\u201338.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"898_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/IJG.0b013e31826a7e09","volume":"23","author":"K Maruyama","year":"2014","unstructured":"Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. J Glaucoma. 2014;23(3):160\u20133.","journal-title":"J Glaucoma"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:06:31Z","timestamp":1709910391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00898-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steven R. Sarkisian Jr. has received research funding from Glaukos, AbbVie, Allysta Pharmaceuticals, Elios Vision, iStar Medical, Ocular Therapeutix, and Sight Sciences; consulting fees from Glaukos, Alcon, AbbVie, Bausch & Lomb, Beaver-Visitec, Icare USA, Ocular Science, and Sight Sciences; payment\/honoraria for lectures\/speaker\u2019s bureau from Aerie Pharmaceuticals, Alcon, AbbVie, and Bausch & Lomb; and owns stock\/stock options in Ocular Science and Sight Sciences. Robert E. Ang has received research funding from Glaukos and honoraria for lectures\/speaker\u2019s bureau from Glaukos. Andy M. Lee has received research funding from Glaukos and Elios Vision; consulting fees from Glaukos; and payment\/honoraria for lectures\/speaker\u2019s bureau from Elios Vision. John P. Berdahl has received consulting fees from Alcon, Bausch & Lomb, Elios Vision, Glaukos, Imprimis, Sight Sciences, ViaLase, and Johnson & Johnson. Sebatian B. Heersink has received research funding from Glaukos, Alcon Research, Allergan, Sight Sciences, EyePoint Pharmaceuticals, Sun Pharmaceuticals, AbbVie, Oyster Point Pharma, Bausch & Lomb, Cloudbreak, Combangio, Genentech, Johnson & Johnson, Ivantis, Kala Pharmaceuticals, Lenstec, Lenz, Nicox Ophthalmics, Noveome and Ocular Therapeutix; consulting fees from Carl Zeiss Meditec Cataract Technology, Bausch & Lomb, and Rayner Intraocular Lenses; and payment\/honoraria for lectures\/speaker\u2019s bureau from Iridex Corporation. James H. Burden has received research funding from Glaukos. Long V. Doan, Kerry G. Stephens, David Applegate, Angela C. Kothe, Dale W. Usner, L. Jay Katz, and Tomas Navratil are employees of Glaukos Corporation and may have received stock and\/or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Human subjects were included in this trial. The trial was undertaken in accordance with the tenets of the Declaration of Helsinki, and with approval of the relevant institutional review board\/independent ethics committee (Western Institutional Review Board, Puyallup, Washington [reference number 20180735] or Wills Eye Hospital Institutional Review Board, Philadelphia, Pennsylvania [reference number 18\u2013763] for sites in the USA, and St. Cabrini Medical Center \u2013 Asian Eye Institute Ethics Review Committee, Makati City, Philippines [reference number 2018\u2013023] for the single site in the Philippines). All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}